By incorporating Sterinow® asset into its state-of-the-art portfolio solutions, TRASIS aims to transform the production processes for radiopharmaceuticals globally, setting new standards in the quality and safety of these manufacturing processes. This pioneering automation innovation streamlines and secures the critical sterility testing step in the production of radiopharmaceuticals, while fully aligning with the highest regulatory and quality standards, setting a new benchmark for the industry.
"We are excited to collaborate with TRASIS to make our innovative RADIOSTER® technology available to a global clientele through the Sterinow® automated solution which aligns with our goal of enhancing radiopharmaceutical safety and ensuring high-quality patient treatments," said Dirk Freitag-Stechl, Managing Director of CUP Contract Labs.
Gauthier Philippart, CEO of TRASIS, commented, "Integrating the Sterinow® automated solution into our portfolio enables us to offer more advanced, efficient solutions, significantly improving the sterility testing processes and meeting the stringent regulatory standards for pharmaceutical safety."
Notes to Editors
About TRASIS
TRASIS is a leader in the radiopharmaceutical sector, dedicated to the development and offering of comprehensive solutions for the production of radioactive drugs. Trasis’s products, including synthesizers, quality control systems and associated consumables are essential in enhancing the safe and efficient production of radiopharmaceuticals globally.
About CUP Contract Labs
Founded in 1991 and based in Radeberg, Germany, CUP Contract Labs specializes in chemical and microbiological GMP testing services, focusing particularly on radiopharmaceuticals. The company is renowned for its adherence to GMP and FDA standards, ensuring top-quality testing services.